Liquid biopsy is a sophisticated cancer diagnostic technique that looks for the disease using biofluids such as blood, cerebrospinal fluid (CSF), plasma, and urine. Circulating nucleic acids, circulating tumor cells (CTC), and exosomes are used as biomarkers in this non-invasive diagnostic procedure to identify cancer.
A significant element
driving the expansion of the worldwide Liquid Biopsy Market during the anticipated period is the
rising incidence of cancer. For instance, the World Health Organization reports
that 9.6 million fatalities and 18.1 million new cases of cancer were reported
globally in 2018.
It is a ground-breaking
method that has opened up numerous prospects that were never before considered.
In addition to being a source of proteomics and genomics data for cancer
patients, it helps in the detection and separation of circulating tumor DNA,
exosomes, and circulating tumor cells.
Liquid Biopsy Market is an easy, quick,
non-invasive, and repeatable sampling technique that can accurately reflect
changes in the gene expression profile of the tumor and serve as a solid
foundation for a customized treatment and cancer early detection. In addition,
recent years have seen an emphasis on early cancer detection, tracking tumor
progression, evaluating therapy response & clinical prognosis, and spotting
recurrent & refractory cancers. In addition, due to recent advancements in
technology addressing both practicality and turnaround time, liquid biopsy has
recently attracted considerable attention as a non-invasive alternative
approach to tissue biopsy in patients with cancer.
The next-generation sequencing for advanced cancer patients using liquid biopsies, an increase in the number of cancer patients, and a rise in patient demand for minimally invasive therapies are all contributing to the growth of the liquid biopsy market. However, the lack of knowledge of liquid biopsy in developing nations limits business expansion. The use of Liquid Biopsy Market testing to treat uncommon cancers and the rise in healthcare spending in developing nations like China and India, however, are likely to create several potentials for market expansion.
The market for Liquid Biopsy
Worldwide: Competitive Scenario
Biocept, Inc., Qiagen
N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera,
Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics
Corporation, and Sysmex Corporation are major participants in the global liquid
biopsy market.
Comments
Post a Comment